The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

Among trial finishers, omalizumab and oral immunotherapy offered similar protection against food allergies, and some people ...

Omalizumab (Xolair) injections outperformed oral immunotherapy (OIT) in increasing tolerance among children with multi-food allergy, largely because many patients couldn't tolerate OIT, findings from ...

Clinical trial shows omalizumab (Xolair) treats multiple severe food allergies more effectively than oral immunotherapy, with ...

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively ...

Omalizumab was found to be more effective than multi-allergen oral immunotherapy (OIT) in reducing allergic reactions in patients with 1 or more food allergies, according to results from Stage 2 of ...

The high rate of side effects from oral immunotherapy in the NIH trial explains the superiority of omalizumab. A clinical ...

Omalizumab superior to oral immunotherapy for multifood allergy, and most patients consume allergy-triggering foods after gaining tolerance.

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ -- Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and only biosimilar ...

OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable ...